EUVIMEDOpdag EUVIMED
Crossref

Bioactive Peptide HX ‐ 12C Ameliorates Oral Submucous Fibrosis via Inhibition of TGF ‐β/Smad‐Driven Myofibroblast Activation: A Potential Therapeutic Strategy

Weiman Huang, Rujie Shi, Yujing Wang, Xidi Wang, Zuodong Qin, Xiaofang Luo, Kun Li iD, Baisheng Wang, Yanjia Hu iD

Oral Diseases · 2026-11-10

DOI: 10.1111/odi.70569 ↗

At a glance

Journal article in Oral Diseases, published online on 2026-11-10. Written by Weiman Huang and 8 co-authors. Institution: Hunan Key Laboratory of Oral Health Research, Hunan 3D Printing Engineering Research Center of Oral Care, Hunan Clinical Research Center of Oral Majo…. 50 references. Funded by: Natural Science Foundation of Changsha, Hunan Provincial Graduate Research and Innovation Project, Innovation Project for Postgraduates of Central South University.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objectives

To investigate the anti‐fibrotic effects and mechanism of action of the bioactive peptide HX‐12C in oral submucous fibrosis. Materials and Methods Primary human buccal mucosal fibroblasts were treated with arecoline to induce a myofibroblast phenotype. The effects of HX‐12C on cell proliferation, migration and fibrotic markers were assessed. Molecular docking and immunofluorescence were used to examine HX‐12C binding to transforming growth factor‐beta receptor I, validated by the inhibitor SB‐431542. In vivo efficacy was evaluated in a bleomycin‐induced rat model of oral submucous fibrosis.

Results

HX‐12C promoted fibroblast proliferation and migration but suppressed arecoline‐induced myofibroblast activation, downregulating alpha‐smooth muscle actin, fibronectin and collagens I/III. Mechanistically, HX‐12C bound to transforming growth factor‐beta receptor I, inhibited SMAD2/3 phosphorylation and downstream pro‐fibrotic gene expression, effects attenuated by SB‐431542. In vivo, HX‐12C improved mouth opening and reduced collagen deposition.

Conclusions

HX‐12C exerts potent anti‐fibrotic effects by directly targeting transforming growth factor‐beta receptor I and inhibiting the canonical transforming growth factor‐beta/Smad signalling pathway. Our findings identify HX‐12C as a promising therapeutic candidate for oral submucous fibrosis and provide a rationale for developing peptide‐based therapies for transforming growth factor‐beta‐driven fibrotic diseases.

Subjects

Author keywords

HX‐12CTGF‐β/Smad signallingarecolinebioactive peptidefibroblastmyofibroblastoral submucous fibrosis (OSF)

Authors and institutions

  • Hunan Key Laboratory of Oral Health Research, Hunan 3D Printing Engineering Research Center of Oral Care, Hunan Clinical Research Center of Oral Major Diseases and Oral Health, Xiangya Stomatological Hospital and Xiangy…
  • Hunan Engineering Technology Research Center for Comprehensive Development and Utilization of Biomass Resources, College of Chemistry and Bioengineering, Hunan University of Science and Engineering, Yongzhou, Hunan, Chi…

ORCID profiles: Kun Li, Yanjia Hu

Funding

  • Natural Science Foundation of Changsha
  • Hunan Provincial Graduate Research and Innovation Project
  • Innovation Project for Postgraduates of Central South University

Cite

APA

Huang, W., Shi, R., Wang, Y., Wang, X., Qin, Z., Luo, X., Li, K., Wang, B., & Hu, Y. (2026). Bioactive Peptide HX ‐ 12C Ameliorates Oral Submucous Fibrosis via Inhibition of TGF ‐β/Smad‐Driven Myofibroblast Activation: A Potential Therapeutic Strategy. Oral Diseases. https://doi.org/10.1111/odi.70569

Vancouver

Huang W, Shi R, Wang Y, Wang X, Qin Z, Luo X, et al. Bioactive Peptide HX ‐ 12C Ameliorates Oral Submucous Fibrosis via Inhibition of TGF ‐β/Smad‐Driven Myofibroblast Activation: A Potential Therapeutic Strategy. Oral Diseases. 2026. doi:10.1111/odi.70569

BibTeX
@article{Huang2026,
  author = {Huang, Weiman and Shi, Rujie and Wang, Yujing and Wang, Xidi and Qin, Zuodong and Luo, Xiaofang and Li, Kun and Wang, Baisheng and Hu, Yanjia},
  title = {Bioactive Peptide HX ‐ 12C Ameliorates Oral Submucous Fibrosis via Inhibition of TGF ‐β/Smad‐Driven Myofibroblast Activation: A Potential Therapeutic Strategy},
  journal = {Oral Diseases},
  year = {2026},
  doi = {10.1111/odi.70569}
}
Start for free →